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Impact of opioid substitution therapy for Scotland’s
prisoners on drug-related deaths soon after prisoner
release
Sheila M. Bird1, Colin M. Fischbacher2, Lesley Graham2 & Andrew Fraser3
MRC Biostatistics Unit, Cambridge, UK,1 NHS National Services Scotland, Edinburgh, UK2 and NHS Health Scotland, Edinburgh, UK3
ABSTRACT
Aim To assess whether the introduction of a prison-based opioid substitution therapy (OST) policy was associated with a
reduction in drug-related deaths (DRD) within 14days after prison release. Design Linkage of Scotland’s prisoner
database with death registrations to compare periods before (1996–2002) and after (2003–07) prison-based OST
was introduced. Setting All Scottish prisons. Participants People released from prison between 1 January 1996 and
8October 2007 following an imprisonment of at least 14days and at least 14weeks after the preceding qualifying release.
Measurements Risk of DRD in the 12weeks following release; percentage of these DRDs which occurred during the ﬁrst
14days. Findings Before prison-based OST (1996–2002), 305 DRDs occurred in the 12weeks after 80200 qualifying
releases, 3.8 per 1000 releases [95% conﬁdence interval (CI) =3.4–4.2]; of these, 175 (57%) occurred in the ﬁrst 14days.
After the introduction of prison-based OST (2003–07), 154 DRDs occurred in the 12weeks after 70317 qualifying
releases, a signiﬁcantly reduced rate of 2.2 per 1000 releases (95% CI=1.8–2.5). However, there was no change in the
proportion which occurred in the ﬁrst 14days, either for all DRDs (87: 56%) or for opioid-related DRDs.
Conclusions Following the introduction of a prison-based opioid substitution therapy (OST) policy in Scotland, the rate
of drug-related deaths in the 12weeks following release fell by two-ﬁfths. However, the proportion of deaths that occurred
in the ﬁrst 14days did not change appreciably, suggesting that in-prison OST does not reduce early deaths after release.
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INTRODUCTION
It is recognized both in the United Kingdom [1–3] and
internationally [4] that recently released prisoners, notably
those with a history of having injected heroin, are at very
high risk of drug-related death (DRD). This increased risk
is concentrated in the ﬁrst 2weeks after release from
prison. For example, Seaman et al. [1] reported that male
HIV-infected drug injectors released from Edinburgh Prison
during 1983–94 had a relative risk (RR) of DRD of 8 [95%
conﬁdence interval (CI)=1.5–39] during the ﬁrst 2weeks
after release versus other comparable times at liberty. Bird
& Hutchinson found that males aged 15–35years had a
DRD risk seven times (95% CI=3.3–16) higher in the ﬁrst
than per 2 weeks in the subsequent 10 weeks [2]. Further,
60% of DRDs within 12weeks of release had occurred
within the ﬁrst 2weeks. These ﬁndings have since been
conﬁrmed in record-linkage studies in England and
Wales [3], Australia [5] and the United States [4].
Subsequently, there have been other studies of DRDs
soon after release from Asia, northern Europe and the
United States [6–10].
The loss of opiate tolerance while in prison may lead
to fatal overdose if opiate use is resumed after release
from prison. Opiate substitution therapy (OST) aims to
reduce the use of illegal and injected opiates by providing
safer substitutes such as oral methadone. Provision of
OST in prisons, besides being good clinical practice, seems
to have contributed to a reduction of in-prison deaths
[11], including suicides by younger inmates [12] and of
injecting while in prison, with its attendant risks of
blood-borne virus transmission [13–17]. Another possible
beneﬁt of prison-based OST might be to prevent the loss of
opiate tolerance and so reduce the risk of DRD after
release. Theoretically, this impact is likely to be greatest
in the early period after release, particularly the ﬁrst
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2weeks, as after this time continued opiate use is likely to
lead to opiate tolerance being re-acquired. However, the
extent to which prison-based OST has actually reduced
these early risks is an open question. In New South Wales
(NSW), prison-based OST was introduced in the late
1980s [5], but Merrall et al. found that the RR for DRD
in the ﬁrst 2weeks after prisoner release actually rose,
from 4.0 (95% CI=3.3–4.8) in 1988–92 to 5.1 (95%
CI=3.8–6.9) in 1998–2002 [4].
Despite NSW’s long-established policy of prison-based
OST, Degenhardt et al. [18] reported that the proportion
of 12-week DRDs that occurred in the ﬁrst 2weeks was
approximately 50% in 2000–10, unchanged from 1988
to 2002 [4,5], although prison-based OST had been
received in 58% of opiate-dependent clients’ prison
episodes.
We are not aware that any prison jurisdictions, other
than NSW [4,5,18], have monitored the impact of
prison-based OST on DRD risk soon after prison release.
When Stallwitz & Stover summarized the published
literature on the impact of OST in prisons, neither
reduction of in-prison mortality nor reduction in early
post-release risk of DRDwas among the speciﬁed goals [19].
In summary, no before-and-after evaluation of how
prison-based OST policy impacts on DRDs soon after
release has been published. Instead, analysts have focused
only on those who did or did not receive prison-based
OST when on offer [18]. We therefore aimed to discover
whether a policy of prison-based OST was associated with
a reduction in early DRD risk, speciﬁcally during the ﬁrst
2weeks after prison release.
The Scottish Prison Service introduced OST in Scottish
prisons in 2002 [20]. Opiate users who report that they
had been receiving methadone maintenance therapy
prior to prison entry and who also have a positive urine
test for methadone are eligible for the programme.
Treatment consists of daily oral doses of methadone
administered under supervision throughout the prison
stay. In a small number of cases, buprenorphine is used
instead of methadone. Opiate users who had not been
receiving methadone prior to prison entry receive
detoxiﬁcation treatment. Prison-based OST was imple-
mented rapidly in Scottish prisons, with 14% of all
prisoners receiving methadone in 2003 and 21% by
2010 [21,22]. Taylor et al. reported that, in 2010, 57%
of Scotland’s prisoners with a history of injection drug
use were receiving OST, a level similar to that reported
in NSW [18].
We investigated whether the risk of DRDwithin the ﬁrst
12weeks after prison release fell between 1996–2002
(before Scotland’s prison-based OST programme) and
2003–07 (after its introduction), andwhether an in-prison
OST policy was associated with a fall in the proportion of
12-week DRDs occurring in the ﬁrst 2weeks.
METHODS
Graham and colleagues [23] linked the records of all those
in Scottish prison custody between 1 January 1996 and
31December 2007 to routine death registrations,
generating a retrospective cohort study that provided
cause-speciﬁc information on deaths up to 31December
2007. Follow-up information was based on death
registration [24]: where there was no such registration,
the individual was assumed to be alive. As our investigation
was not one of the original objectives of the Graham study,
a variation on permissions was approved by Scottish Prison
Service’s Research Access and Ethics Committee and by
Scotland’s Privacy Advisory Committee.
Statistical methods
We restricted our study to qualifying releases, which
were deﬁned as: ‘release on or after 1 January 1996 (and
up to 8October 2007) that occurred after an imprison-
ment of at least 14days and at least 14weeks after the
date of the preceding qualifying release’. The restriction
to 8October 2007 was to allow a 12-week mortality
follow-up for all releases in 2007, as mortality data were
available only up to 31December 2007. The restriction
to releases at least 14weeks after a previous release
allowed for 12 weeks’ follow-up for mortality after the
preceding release, as in previous studies [2,25], plus
2weeks asminimal length of imprisonment before the next
qualifying release. We excluded imprisonments of less than
14days on the grounds that these were too short to lead to
loss of opiate tolerance.
Our power calculation assumed that prior to OST
introduction (in 1996–2002), 60% of DRDs within
12weeks after release would occur in the ﬁrst 2weeks, as
reported previously in Scotland [2], and that after the
introduction of OST this would fall to approximately 47%,
the ﬁgure observed in NSW when OST was widely used
[4,5]. To detect such a change, the comparison periods
would each have to contribute approximately 230DRDs
in the 12weeks after qualifying releases for 80% power at
the 5% signiﬁcance level.
From the linked prisoner-mortality database held at
Information Services Division, Scotland, we calculated
the number of deaths that occurred at liberty among
ex-prisoners in the 12weeks after the prisoners’ qualifying
for prison release, by age group at release (15–34 years and
35+ years) and for the periods before and after the
introduction of prison-based OST. Our assignment of
exposure to in-prison OST was therefore based on whether
the prisoner was released before the introduction of
prison OST in Scotland (1996–2002) or during a period
(2003–07) when the use of OST was widespread, as
conﬁrmed by the previously cited surveys [13,21,22].
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Deaths were analysed for two periods before the
introduction of OST (1996–99 and 2000–02) and for
two periods after (2003–05 and 2006–07). We excluded
any in-prison death which coincided with the deceased’s
liberation date and was not recorded as having occurred
in the outside community. We deﬁned deaths as DRDs
using the wide deﬁnition of the Ofﬁce for National
Statistics, which includes deaths where the underlying
cause is coded to the following International Disease
Classiﬁcation (ICD) codes: 292, 304, 305.2–9, E850–858,
E950.0–5, E962.0 and E980.0–5 (ICD-9 for 1996–99)
or F11–F16, F18, F19, X40–X44, X60–X64 and
Y10–Y14 (ICD-10 from 2000). Full description of these
codes is given in the Supporting Information. We
calculated the number of 12-week DRDs that occurred in
the ﬁrst 2weeks after the qualifying prison release and the
risk of DRD in the 12weeks post-release (per 1000 qualify-
ing releases; and per 100person-years at risk, which takes
follow-up time and re-imprisonment into account). We
calculated person-days at liberty in the ﬁrst 12weeks after
a qualifying release from the day of release up to the earliest
of: date of death, date of re-incarceration for at least 14days
or 12weeks after the qualifying release date.
We used the ﬁrst 2weeks and 12-week DRD totals for
1996–2002 and 2003–07 to compare the percentage of
12-week DRDs that had occurred in the ﬁrst 2weeks
post-release before and after the introduction of Scottish
prisons’ OST policy.
In addition, we calculated the number of opioid-related
DRDs in the ﬁrst 2weeks and 12weeks after qualifying
releases for 2000–02 and 2003–07. Data on whether or
not DRDs were opioid-related were not available prior to
2000. DRDswere deﬁned as opioid-relatedwhen toxicolog-
ical information indicated that any of heroin, morphine,
methadone or buprenorphine was implicated in, or had
contributed to, the cause of death. Data extraction was
programmed using Stata version 13 (College Station, TX,
USA). Comparisons were made using χ2 tests and 95%
conﬁdence intervals are Poisson-based.
RESULTS
The study included 150517 prison releases (for 131472
individuals) between 1 January 1996 and 31December
2007, 10085 (7%) of which were among females. There
were approximately 11450 qualifying releases per annum
during 1996–02 and 16250 per annum in 2006–07
(Table 1). DRDs accounted for 70% (95% CI=66–74%)
of all deaths in the 12weeks after prison release in the
younger age group but only 32% (95% CI=27–37%) of
those aged 35years or older.
For all ages combined, the DRD rate in the 12weeks af-
ter prison release fell from 3.7 and 4.0 per 1000 qualifying
releases during two periods before the OST policy to 2.4 and
1.9 during two periods after (Table 2). Overall, the 12-week
DRD rates per 1000 qualifying releases fell from 3.8 (95%
CI=3.4–4.2) to 2.2 (95% CI=1.8–2.5) after the introduc-
tion of the OST policy. The fall in rates (1.6 per 1000;
95% CI=1.0–2.2) was highly statistically signiﬁcant
(χ2 on 1 d.f. =32.0, P<0.00001), and evident in both
age groups. There was a similar fall in DRD risk when it
was expressed per 100 person-years in the 12-weeks
post-release, the rate falling from 1.9 (95% CI=1.6–2.1)
to 1.2 (95% CI=1.0–1.4) after the introduction of OST.
However, an analysis that focused more speciﬁcally on
early drug deaths did not show such a fall. Table 3 shows
that among those DRDs that occurred in the 12weeks
after release there was no appreciable change in the
proportion that occurred within the ﬁrst 2weeks (57%;
95% CI=52–63% before the introduction of OST and
56%; 95% CI=48–64% after). The change in the percent-
age of early deaths was only –1% (95% CI= –11–9%).
Table 1 Drug-related deaths (DRDs) and total deaths in the 12weeks after release from Scottish prison custody during two periods
(1996–99 and 2000–02) before and two periods (2003–05 and 2006–07) after the introduction of Scotland’s prison-based opioid
substitution therapy (OST) policy, by age group.
Period
Age group at release
Combined age groups 15–34 years 35+ years
Qualifying releases


















1996–99 46058 (11 515) 169/276 (61%) 3.7 (3.1–4.2) 37067 146/207 (78%) 8991 23/69 (33%)
2000–02 34142 (11 381) 136/210 (65%) 4.0 (3.3–4.7) 26460 103/135 (76%) 7682 33/75 (44%)
2003–05 41872 (13 957) 100/196 (51%) 2.4 (1.9–2.9) 31137 81/114 (71%) 10735 19/82 (23%)
2006+07 28445 (16 254) 54/130 (42%) 1.9 (1.4–2.4) 20563 37/ 69 (54%) 7882 17/61 (28%)
Totals 150 517 459/817 (56%) 115 227 367/525 (70%) 35290 92/287 (32%)
CI = conﬁdence interval.
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These ﬁndings were similar when the analysis was re-
stricted to opiate-related DRDs (Table 4), although this
information was only available for the period 2000–07.
For opiate-related DRDs, the reduction in the percentage
of deaths occurring within 2weeks was again –1% (95%
CI= –13–11%), from 62% before the OST policy to 61%
afterwards.
DISCUSSION
Statement of principal ﬁndings
The DRD-rate in the ﬁrst 12weeks following release fell
from 3.8 per 1000 qualifying releases in 1996–2002 be-
fore the introduction of the in-prison OST policy to 2.2 per
1000 afterwards. This reduction was signiﬁcant (P<0.01)
in both age-groups, and similar whether measured per
1000 qualifying releases or per 100 person-years at liberty.
However, the percentage of these DRDs that occurred in
the ﬁrst 2weeks after release did not reduce appreciably, a
ﬁnding which does not support the suggestion that OST
would reduce DRDs in the immediate period after release.
Strengths and weaknesses of the study
One weakness of our study was that for deaths during
1996–99 we did not have access to the post-mortem toxi-
cology information required to classify deaths as
opioid-related in accordance with the United Kingdom’s
harmonized DRD deﬁnition. However, for ICD-10-coded
DRDs during 2000–07 the majority of DRDs soon after
release were opiate-related DRDs, and so this issue is
Table 2 Drug-related death risk (DRD risk) in the 12weeks after release from at least 14 days in Scottish prison custody: before
(1996–2002) and after (2003–07) prison-based opioid substitution therapy (OST) was introduced.
Period




DRDs in 12 weeks post-release
per 1000 releases (95% CI)
Person-years at risk in
12 weeks post-release
DRD rate per 100 person-years in
the 12 weeks post-release (95% CI)
Age group at release: 15–34 years
1996–2002 249 63527 3.9 (3.4–4.4) 12828 1.9 (1.7–2.2)
2003–2007 118 51700 2.3 (1.9–2.7) 9398 1.3 (1.0–1.5)
Age group at release: 35+ years
1996–2002 56 16673 3.4 (2.5–4.2) 3484 1.6 (1.2–2.0)
2003–2007 36 18617 1.9 (1.3–2.6) 3558 1.0 (0.7–1.3)
Combined age groups
1996–2002 305 80200 3.8 (3.4–4.2) 16312 1.9 (1.7–2.1)
2003–2007 154 70317 2.2 (1.8–2.5) 12956 1.2 (1.0–1.4)
CI = conﬁdence interval.
Table 3 Percentage of 12-week drug-related deaths (DRDs) that occurred in the ﬁrst 2weeks after release: before (1996–2002) and after
(2003–07) prison-based opioid substitution therapy (OST) became the health-care standard in Scottish prisons.
Period
Age group at release
Combined age groups 15–34 years 35+ years
DRDs in ﬁrst 2 weeks: as
percentage of 12-week DRDs
95% CI for ﬁrst
2 weeks percentage
DRDs in ﬁrst 2 weeks: as
percentage of 12-week DRDs
DRDs in ﬁrst 2 weeks: as
percentage of 12-week DRDs
1996–2002 175: 57% of 305 52–63% 146: 59% of 249 29: 52% of 56
2003–2007 87: 56% of 154 48–64% 70: 59% of 118 17: 47% of 36
Totals 262: 57% of 459 52–62% 216: 59% of 367 46: 50% of 92
CI = conﬁdence interval.
Table 4 Percentage of 12-week opioid drug-related deaths (DRDs)
in 2000–07 that occurred in the ﬁrst 2weeks after release: before
(2000–02) and after (2003–07) prison-based opioid substitution
therapy (OST) was introduced in Scottish prisons.
Period*
First 2 weeks: combined age groups
Opioid-DRDs in ﬁrst
2 weeks: as percentage of
12-week opioid DRDs
95% CI for ﬁrst
2 weeks percentage*
2000–2002 72: 62% of 117 53–70%
2003–2007 80: 61% of 132 52–69%
Totals 152: 61% of 249 55–67%
*There were four DRDs in 2000–02 and four in 2003–07 for whom toxi-
cology could not be linked. Hence, 132/150 linked DRDs in 2003–07
(88%) and 117/132 linked DRDs in 2000–02 (86%) were opioid DRDs.
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unlikely to affect our conclusions. Further, the results of
the analysis restricted to opioid-related DRDs were the
same as the main analysis.
Death registration in Scotland is highly complete and
timely [24]. A small number of deaths may have been
missed because they occurred outside Scotland. Some
deaths could have been missed because of inaccurate data
linkage, but estimates based on clerical checking suggest
that rates of false positive or negative linkage are below
1% [26].
We did not have information about whether individual
prisoners received OST during their preceding term of
imprisonment. However, as noted previously, surveys
indicated high levels of usage of OST in Scottish prisons
after the introduction of the policy [13,21,22]. We do not
know how many releases were of opioid-dependent
individuals. Unlike Degenhardt et al. [18], our goal was a
before-and-after evaluation of the policy of prison-based
OST, rather an explanatory analysis at the individual level
of whether opioid-dependent prisoners beneﬁted from
in-prison OST.
A notable strength of our study is that the numbers
were sufﬁcient to provide a reasonably precise estimate of
the change in the percentage of DRDs that occurred in
the ﬁrst 2weeks. As noted above, the change in this
percentage between 1996–2002 and 2003–07 was –1%
(95% CI= –11–9%). The lower 95% conﬁdence limit of
–11% clearly excludes any substantial reduction.
Interpretation of these results
This study provides no evidence that in-prison OSTwas the
cause of the reduced DRD risk during the ﬁrst 12weeks
after release. A possible alternative explanation is that the
proportion of prisoners who were opioid-dependent
decreased.We cannot rule this out, but we think it unlikely,
as the surveillance of Scottish prisoners’ HIV-risk
behaviours in 1994–96 [15,16] and by Taylor et al. [13]
for 2010 showed that a third of Scottish prisoners had a
life-time history of injection drug use. However, the
proportion who reported having ever injected inside prison
fell from half in the mid-1990s to only a quarter in 2010
[13]. Moreover, 57% of inmates with a history of having
ever injected drugs self-reported that they were receiving
methadone maintenance [13], a ﬁgure similar to that
reported in NSW [18].
We cannot exclude other explanations for the decrease
in DRD rate in the ﬁrst 12weeks post-release. Upturn in
economic prospects could be a possible explanation but,
among the poorest in Scotland, incomes started to fall from
2003 [27], the start of the OST era, which makes this an
unlikely explanation.
A much more likely explanation of the observed fall in
the 12-week DRD risk is the contribution of improved
quality assurance in methadone prescribing in the outside
community. During 1996–2007 access to, and the safety
of, methadone prescriptions in Scotland increased in the
outside community [28], accompanied by a reduction in
DRD risk [29–31]. Strang et al. [28] showed that there
was a substantial reduction in methadone-related deaths
in Scotland from29 to 13 permillion deﬁned daily doses be-
tween 1996–2002 and 2003–07. More generally, Merrall
[29] showed that Scottish drug treatment clients’ DRD rate
fell from 0.50 per 100 person-years in 1996/97–2000/01
(95% CI=0.45–0.55) to 0.34 in 2001/02–2005/06 (95%
CI=0.30–0.38).
Thus, better quality-assurance in how methadone was
prescribed in Scotland outside its prisons and better
community access to drug treatment may have contrib-
uted to the observed decrease in DRD rate in the ﬁrst
12weeks after qualifying releases in 2003–07. However,
the increased risk of DRD in the ﬁrst 2weeks (that is, the
proportion of 12-week DRDs occurring in the ﬁrst 2weeks)
is unlikely to be affected by these trends.
DRDs formed a larger percentage of deaths in the ﬁrst
12weeks among younger compared to older prisoners.
However, our results do not support the suggestion that
OST is more effective among younger than older prisoners.
The percentage reduction in DRD risk was similar
whether calculated per 1000 qualifying releases or per
100 person-years at liberty [2]. The latter is theoretically
preferable because follow-up time is taken into account
but, in practice, is unavailable in jurisdictions which
cannot track individuals’ re-incarceration, which we did.
Our results support the recommendation by Bird &
Hutchinson [2] that reliable conclusions can be drawn
on the basis of 2- and 12-week DRD rates per 1000
qualifying releases when person-years at risk are not
available.
Setting our results in context of the literature
No previous national study has quantiﬁed the impact of
the policy of prison-based OST on drug-related deaths
within 12weeks after prison release or on the percentage
of those deaths that occur in the ﬁrst 2weeks after re-
lease. A time–series analysis of prison-based OST at Leeds
prison focused on in-prison opioid-related deaths and on
prisoners’ preference for OST over detoxiﬁcation [32].
Degenhardt et al. [18] concluded that the provision of
OST in prison to opiate-dependent prisoners had a short-
term protective effect post-release, which decayed quickly.
Prisoners who actually received prison-based OST experi-
enced a substantial reduction in the hazard of in-prison
death (approximately 0.16 per 100 person-years) [11].
In NSW, as in Scotland, DRDs in the ﬁrst 2weeks after
prison release were three times more frequent than
suicides in prison [2,11,18], and so a reduction in DRDs
Impact of prison OST on DRDs post-release 5
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after release could have a greater impact in saving more
lives.
Policy implications
In Scotland, three-quarters of DRDs are opioid-related. The
total number of DRDs increased by 30% from 288 per
annum in 1996–2002 to 377 in 2003–2007 [33].
However, outside the prison setting, DRD rates for
Scotland’s drug treatment clients have decreased by
approximately 30% [29,30], in accordance with OST’s
general protective effect against DRDs [31], from which
ex-prisoners might also be expected to beneﬁt.
Our ﬁnding that ex-prisoners’ DRD rate in the
12weeks post-release decreased substantially, coinci-
dent with the introduction of OST in Scottish prisons,
is a welcome ﬁnding, even if it is unlikely to be directly
attributable to prison-based OST. Parity in OST provi-
sion with the outside community is the primary reason
that opioid-dependent prisoners should have access to
methadone maintenance [20], and was one reason
for its adoption in Scottish prisons. OST took longer
to implement in England and Wales [32,34] than in
Scotland, and its introduction in Canada was contro-
versial [35]. Neither in Taiwan [36] nor in the United
States [37,38] is OST in prisons an accepted policy, de-
spite community access.
Our results indicate that prison-based OST is unlikely to
reduce the very high DRD risk in the ﬁrst 2weeks after
prison release. This requires further consideration of the
reduced tolerance for opioids during imprisonment, on
one hand, and high-risk behaviours after release on the
other hand. Newly liberated ex-prisoners may be at greater
risk than other opioid-users of relapse into more hazardous
use of heroin [39], such as by injection or in combination
with other respiratory suppressants such as alcohol or
benzodiazepines. Reductions in early DRDs may depend
upon the released prisoner engaging with community-
based OST [11] and may require more speciﬁcally targeted
interventions at the time of release, such as naloxone-
on-release [2,40–42]. Despite our ﬁndings, provision of
OST in prisons is fully justiﬁed on grounds of parity of
health-care and by its contribution to reduction of in-
prison deaths including suicide [11,12] and of injecting
in prison [13–15,17].
A substantial reduction in the proportion of 12-week
DRDs occurring in the ﬁrst 2weeks after prison-release
was not supported by our data. None the less, we
encourage other prison jurisdictions to undertake similar
before-and-after evaluations of their prison-based OST pol-
icy to provide a more deﬁnitive answer than can any sin-
gle jurisdiction on whether a more modest OST-related
decrease might apply; for instance, 15% or from 60 to
51%, with which our data are consistent. Future research
might also aim to collect information on whether
individual prisoners received OST in prison to enable both
an evaluation of prisons’ OST-policy and its uptake by
inmates.
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